KRYS

Krystal Biotech

• Simply Wall St·1d ago

  Does UK Approval of At‑Home VYJUVEK Dosing Reshape the Bull Case for Krystal Biotech (KRYS)?

• Simply Wall St·3d ago

  A Look At Krystal Biotech (KRYS) Valuation After UK Approval And Exclusivity Win For VYJUVEK

• TipRanks·5d ago

  Krystal Biotech (KRYS) Gets a Buy from Bank of America Securities

• Dow Jones·5d ago

  Krystal Biotech Price Target Maintained With a $310.00/Share by HC Wainwright & Co.

• Benzinga·5d ago

  HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $310 Price Target

• TipRanks·5d ago

  Analysts Have Conflicting Sentiments on These Healthcare Companies: Krystal Biotech (KRYS), Immunocore Holdings (IMCR) and Moderna (MRNA)

• PUBT·6d ago

  Corbus Pharma names Nishant Saxena chief business officer

• TipRanks·05/20 10:34

  Krystal Biotech Shareholders Approve Directors and Compensation

• PUBT·05/20 10:03

  Krystal Biotech shareholders elected Krishnan, Mason as Class III directors

• TipRanks·05/18 14:18

  Analyst Reiterates Buy on Krystal Biotech as Vyjuvek Global Launch and Growing Rare-Disease Pipeline Underpin Long-Term Upside

• TipRanks·05/18 12:17

  Krystal Biotech announces UK MHRA approval of Vyjuvek

• Benzinga·05/18 12:05

  Krystal Biotech Says UK MHRA Grants Marketing Authorization To VYJUVEK For Treatment Of Wounds In Patients With Dystrophic Epidermolysis Bullosa With Mutation(s) In COL7A1 Gene, From Birth

• PUBT·05/18 12:04

  Krystal Biotech wins UK MHRA approval for Vyjuvek in dystrophic epidermolysis bullosa

• Reuters·05/18 12:00

  KRYSTAL BIOTECH ANNOUNCES UNITED KINGDOM MHRA APPROVAL OF VYJUVEK® FOR THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA

• Simply Wall St·05/18 11:29

  The Bull Case For Krystal Biotech (KRYS) Could Change Following UK Vyjuvek Approval And Rising Profitability